C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 15/62 (2006.01) A61K 38/16 (2006.01) A61K 47/48 (2006.01) A61P 35/00 (2006.01) C07K 7/08 (2006.01) C07K 14/415 (2006.01) C07K 16/30 (2006.01) C07K 19/00 (2006.01) C12N 15/11 (2006.01) C12N 15/13 (2006.01) C12N 15/29 (2006.01)
Patent
CA 2560278
Modified forms of bouganin protein are provided having biological activity and a reduced propensity to activate human T cells as compared to the non-modified bouganin protein. Also provided are T-cell epitope peptides of bouganin, and modified T-cell epitope peptides of bouganin, which have a reduced propensity to activate human T cells as compared to the non-modified T-cell epitope peptide. Also provided are cytotoxins that comprise a ligand which binds to cancer cells, and is attached to modified bouganin proteins. Also provided are methods of inhibiting or destroying mammalian cancer cells using the cytotoxins and pharmaceutical compositions for treating human cancer.
La présente invention a trait à des formes modifiées de la protéine bouganine présentant une activité biologique et une propension réduite à l'activation des lymphocytes T humains comparée à la protéine bouganine non modifiée. L'invention a également trait à des peptides de site antigénique de lymphocytes T de bouganine, et des peptides de site antigénique de lymphocytes T modifiés de la bouganine, qui présentent une propension réduite à l'activation des lymphocytes T humains comparée au peptide de site antigénique de lymphocytes T non modifié. L'invention a trait en outre à des cytotoxines comportant un ligand se liant à des cellules cancéreuses, et qui est fixé à des protéines bouganine modifiées. Enfin, l'invention a trait à des procédés d'inhibition ou de destruction de cellules cancéreuses mammaliennes mettant en oeuvre les cytotoxines et des compositions pharmaceutiques pour le traitement du cancer humain.
Baker Matthew
Bosc Denis Georges
Carr Francis J.
Cizeau Jeannick
Entwistle Joycelyn
Bereskin & Parr Llp/s.e.n.c.r.l.,s.r.l.
Merck Patent Gmbh
LandOfFree
Modified bouganin proteins, cytotoxins and methods and uses... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified bouganin proteins, cytotoxins and methods and uses..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified bouganin proteins, cytotoxins and methods and uses... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1671159